|
|
By Donielle McCutcheon and Kim Schroer, Sidley Austin LLP
For emerging drug and medical device companies on a tight budget, an effective healthcare compliance program can save precious resources by establishing better oversight, controls, and monitoring of the company’s quality, R&D, clinical, and market access activities. Such a program should be implemented in precommercial stages and will prepare you for the regulated future ahead.
|